Udy on the relation ship involving serum urate level and recurrent

Udy on the relation ship between serum urate level and recurrent attacks of gouty arthritis: proof for reduction of recurrent gouty arthritis with antihyperurice mic therapy. Arthritis Rheum. 2004;51(three):321. 19. Uhlig T, Karoliussen LF, Sexton J, Borgen T, Haavardsholm EA, Kvien TK, et al. 12month outcomes from the reallife observational treattotarget and tightcontrol therapy NORGout study: achievements with the urate target levels and predictors of acquiring this target. RMD Open. 2021;7(1) e001628. 20. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based suggestions for gout. Portion II: Management. Report of a activity force on the EULAR Standing Committee for Interna tional Clinical Research Which includes Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):13124. 21. Stamp LK, Morillon MB, Taylor WJ, Dalbeth N, Singh JA, Lassere M, et al. Variability inside the reporting of serum urate and flares in gout clini cal trials: Will need for Minimum Reporting Specifications. J Rheumatol. 2018;45(3):4194. 22. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The SelfAdministered Comorbidity Questionnaire: a new process to assess comorbidity for clinical and well being services study. Arthritis Rheum. 2003;49(two):1563. 23. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23(2):1375. 24. Ware JE Jr, Gandek B, Group TIP. The SF36 Well being Survey: development and use in mental overall health study plus the IQOLA project. Int J Ment Health. 1995;23:493. 25. Lorig K, Chastain RL, Ung E, Shoor S, Holman HR. Improvement and evaluation of a scale to measure perceived selfefficacy in men and women with arthritis. Arthritis Rheum. 1989;32(1):374. 26. Horne R, Weinman J. Patients’ beliefs about prescribed medicines and their function in adherence to remedy in chronic physical illness. J Psycho som Res. 1999;47(six):5557. 27. Hammer HB, Karoliussen L, Terslev L, Haavardsholm EA, Kvien TK, Uhlig T. Ultrasound shows rapid reduction of crystal depositions throughout a treattotarget approach in gout sufferers: 12month benefits from the NORGout study. Ann Rheum Dis. 2020;79(11):1500. 28. Bayat S, Aati O, Rech J, Sapsford M, Cavallaro A, Lell M, et al. Create ment of a dualenergy computed tomography scoring program for measurement of urate deposition in gout. Arthritis Care Res (Hoboken). 2016;68(six):7695. 29. Uhlig T, Eskild T, Karoliussen LF, Sexton J, Kvien TK, Haavardsholm EA, et al. Twoyear reduction of dualenergy CT urate depositions throughout a treattotarget technique in gout in the NORGout longitudinal study. Rheumatology (Oxford). 2022 (In press). 30. Shiozawa A, Szabo SM, Bolzani A, Cheung A, Choi HK. Serum uric acid along with the risk of incident and recurrent gout: a systematic critique.Apiin Technical Information J Rheumatol.Salvianolic acid A manufacturer 2017;44(3):3886.PMID:22664133 31. Stamp L, Morillon MB, Taylor WJ, Dalbeth N, Singh JA, Lassere M, et al. Serum urate as surrogate endpoint for flares in persons with gout: a systematic review and metaregression analysis. Semin Arthritis Rheum. 2018;48(two):29301. 32. Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, et al. Gout inside the UK and Germany: prevalence, comorbidities and management generally practice 20002005. Ann Rheum Dis. 2008;67(7):960. 33. Mandell BF, Fields TR, Edwards NL, Yeo AE, Lipsky PE. Posthoc evaluation of pegloticase pivotal trials in chronic refractory gout: connection betweenUhlig et al. Arthritis Research Therapy(2022) 24:Page 11 of34.35. 36.37.38. 39. 40. 41.fluctuations in plas.